Entering a new market is rarely limited by demand — it is limited by dossier readiness. Across the 30+ countries where Alvita operates, we’ve found that the single biggest driver of approval speed is how well a CTD dossier is tuned to the destination regulator’s specific expectations, not just ICH baseline requirements.

Why generic dossiers stall

A dossier built for EU-GMP submission rarely transfers cleanly to WHO-GMP or ANVISA review without rework. Query cycles that could take two weeks often stretch to two months when documentation wasn’t pre-validated against the receiving authority’s checklist.

Our approach

• Country-specific CTD formatting from day one, not retrofitted later

• Mock audits run against the actual reviewing authority’s known query patterns

• A dedicated RA lead who owns query resolution end-to-end, replying within one business day

The result: clients moving from concept to market authorization in as little as 2 months for streamlined markets, versus the 12+ months common with generic submissions.

"The result: clients moving from concept to market authorization in as little as 2 months for streamlined markets."